ASCO Meeting News Research News and Press Releases

Testosterone fuels the growth of prostate cancer. The target of testosterone is the androgen receptor. Metastatic prostate cancer is treated by reducing levels of testosterone, and despite initial responses to treatment, nearly all patients become resistant to androgen deprivation therapy.

Research Results MEDICINE

Released: 29-May-2024 11:05 AM EDT

Tumor microbiome differences in early-onset versus average-onset pancreatic adenocarcinoma

Case Western Reserve University

Research Alert MEDICINE

Newswise: 8d050f29-dcb2-4255-8b46-ab0a8523d4ed

Released: 29-May-2024 11:05 AM EDT

Reducing Radiation After Surgery Prolongs Survival for Some Patients With HPV-Related Throat Cancer

Yale Cancer Center/Smilow Cancer Hospital

Patients being treated for HPV-related oropharynx cancer might need less radiation therapy typically given post-surgery, according to a new study.

Research Results MEDICINE

Released: 29-May-2024 11:05 AM EDT

Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)

Case Western Reserve University

Research Alert MEDICINE

Released: 29-May-2024 11:05 AM EDT

Safety and efficacy of first-in-class CXCR1/2 inhibitor SX-682 in combination with pembrolizumab (pem) in patients (pts) with metastatic melanoma (mMEL) with disease progression on anti–PD-1 therapy.

Sylvester Comprehensive Cancer Center

Research Alert MEDICINE

Released: 29-May-2024 11:05 AM EDT

Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation.

Sylvester Comprehensive Cancer Center

Research Alert MEDICINE

Released: 29-May-2024 11:05 AM EDT

Evaluation of a polygenic risk score as a predictor of early onset triple-negative breast cancer in Black women

Case Western Reserve University

Research Alert MEDICINE

Released: 29-May-2024 9:05 AM EDT

American Cancer Society Researchers Presenting Key Studies at 2024 ASCO Meeting

American Cancer Society (ACS)

Scientists from the American Cancer Society (ACS) are presenting important research studies at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2024.

Research Results MEDICINE

Released: 29-May-2024 6:05 AM EDT

Filling the gap in competency-based training for medical oncology with supervised online patient counseling: A qualitative study

Mercy Medical Center

Research Alert MEDICINE

Released: 28-May-2024 9:00 AM EDT

ASCO: MD Anderson’s Sharon Giordano and Richard Gorlick honored as 2024 Special Awards Recipients

University of Texas MD Anderson Cancer Center

In honor of their outstanding contributions to the field of oncology, two researchers from The University of MD Anderson Cancer Center will be honored with Special Awards at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Announcement MEDICINE

Released: 24-May-2024 4:05 PM EDT

Pathways Study Genotype Data, Alliance A011502 Secondary Analysis Headline Roswell Park ASCO24 Presentations

Roswell Park Comprehensive Cancer Center

New insights on improving clinical outcomes and quality of life among breast cancer patients highlight the slate of new research presentations Roswell Park Comprehensive Cancer Center experts will deliver at the American Society of Clinical Oncology (ASCO) Annual Meeting at McCormick Place in Chicago next week.

Research Results MEDICINE

Released: 24-May-2024 1:05 PM EDT

Phase Ib Study of Regorafenib (REG) Plus Pembrolizumab (PEMBRO) for First-Line Treatment of Advanced Hepatocellular Carcinoma (HCC)

Keck Medicine of USC

Research Alert MEDICINE

Newswise: Breaking Barriers for Cancer Clinical Trials: A Multi-Tiered Interventional Approach to Boost Racial and Ethnic Minority Participation in Early-Phase Studies

Released: 24-May-2024 12:05 PM EDT

Breaking Barriers for Cancer Clinical Trials: A Multi-Tiered Interventional Approach to Boost Racial and Ethnic Minority Participation in Early-Phase Studies

Keck Medicine of USC

Research Alert MEDICINE

Released: 24-May-2024 11:05 AM EDT

New Survival Data From a Lung Cancer Study to be Revealed by Yale Cancer Center Expert at International Conference

Yale Cancer Center/Smilow Cancer Hospital

“The COAST study, which we began five years ago, involves patients who get chemotherapy and radiation therapy for lung cancer. And now we know that we can improve the outcome with a drug called durvalumab,” explained Dr. Herbst, who will present the findings at ASCO.

Research Results MEDICINE

Newswise: 1920_asco-advisory-cedars-sinai.jpg?10000

Released: 24-May-2024 10:05 AM EDT

Cedars-Sinai Experts Present Cancer News at ASCO Annual Meeting

Cedars-Sinai

Cedars-Sinai Cancer physician-scientists and thought leaders will discuss scientific advances, new therapies, and the future of cancer care at the American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31-June 4 in Chicago.

Announcement MEDICINE

Newswise: ASCO: Large precision oncology study identifies differences in prostate cancer genomics among a racially and ethnically diverse cohort of U.S. veterans

Released: 24-May-2024 10:05 AM EDT

ASCO: Large precision oncology study identifies differences in prostate cancer genomics among a racially and ethnically diverse cohort of U.S. veterans

University of California, Los Angeles (UCLA), Health Sciences

A new study(Link is external) (Link opens in new window) led by a UCLA-VA collaborative team looking at the landscape of genomic alterations in more than 5,000 veterans with metastatic prostate cancer uncovered differences in the genomic makeup of cancer cells that were associated with race and ethnicity.

Research Results MEDICINE

Expert Pitch

Expert Query

Expert Directory

Feature Channels: ASCO Meeting News

Filters close

Safety and efficacy of osimertinib plus consolidative stereotactic ablative radiation (SABR) in advanced EGFR mutant non-small cell lung cancer (NSCLC): results from a multi-center Phase II trial

ARC-9: A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC).

A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer.

ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study.

Phase 1/2 trial of the XPO1 inhibitor selinexor in combination with docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer (NSCLC)

Fibrolamellar hepatocellular carcinoma (FL-HCC) epidemiology, survival characteristics, and outcomes: Surveillance, epidemiology, and end results database (SEER) study

Association between congenital heart disease and cancer: A meta-analysis of 30 million patients

Clinically significant variant classification resulting from the addition of RNA sequencing: Experience at high-volume cancer genetics center

Cancer screening in sexual and gender minority populations: A systematic review and meta-analysis

Non-Hodgkin lymphoma mortality disparities across different sexes, races, and geographic locations

A meta-analysis of models for predicting the incidence of brain metastasis in patients with lung cancer

Evaluating the impact of socioeconomic status on patient satisfaction in radiation oncology

Impact of race and ethnicity on financial toxicity in patients with genitourinary cancers

Trilaciclib use for prevention of hematological adverse events in chemotherapy: A meta-analysis of real-world studies and clinical trials

The effect of resting dendritic cells on overall survival in the hepatocellular carcinoma tumor microenvironment

Epidemiology, symptomatology, diagnosis and clinical implications of cystic tumors of atrioventricular node (CTAVN): A systematic review

Socioeconomic disparities in survival outcomes of patients with SCLC with brain metastases: A nationwide analysis

Trend and burden of cancer related hospitalizations in the US: Insights from a National Inpatient Sample Database analysis

End-of-life care preferences in patients with gallbladder cancer: Shifting patterns and disparities over two decades

Clustering analysis for predicting racial disparities in genitourinary cancer–related financial burden

Changes in US colorectal cancer mortality trends over the past 20 years

Socioeconomic disparities in survival outcomes of patients with NSCLC with brain metastases: A real-world analysis

Trends in hospice utilization and place of death preferences in multiple myeloma-related deaths from 2003 to 2020: Analysis of CDC Wonder database

Impact of body mass index (BMI) on survival outcomes in patients with cancer treated with immune checkpoint inhibitors (ICPI): A systematic review and meta analysis

A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO): NRG-BR008.

Next-generation sequencing in patients with lung cancer undergoing immunotherapy: Retrospective analysis

Ethnic disparities in biomarker testing of patients with metastatic NSCLC in the United States: A real-world analysis

Survival outcomes of small cell variant bladder cancer: Analysis from nationwide study

Preliminary safety and efficacy of oral azacitidine (Oral-AZA) in patients (pts) with low-/Intermediate (Int)-risk myelodysplastic syndromes (MDS): Phase 2 results from the ASTREON trial.

Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma

Assessing gender disparities in oncology: Less talk, more action

StrateGIST 1: A first-in-human (FIH), phase 1 study of IDRX-42 in patients with metastatic gastrointestinal stromal tumors resistant to prior treatment with tyrosine kinase inhibitors (TKIs)

Phase II multi-center study of adjuvant nivolumab in combination with ipilimumab in patients with high-risk uveal melanoma (HCRN MEL17-309)

Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial

A Promising New Targeted Therapy for Patients with Metastatic Prostate Cancer with Therapy-Resistant Mutations

Tumor microbiome differences in early-onset versus average-onset pancreatic adenocarcinoma

Reducing Radiation After Surgery Prolongs Survival for Some Patients With HPV-Related Throat Cancer

Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)

Safety and efficacy of first-in-class CXCR1/2 inhibitor SX-682 in combination with pembrolizumab (pem) in patients (pts) with metastatic melanoma (mMEL) with disease progression on anti–PD-1 therapy.

Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation.

Evaluation of a polygenic risk score as a predictor of early onset triple-negative breast cancer in Black women

American Cancer Society Researchers Presenting Key Studies at 2024 ASCO Meeting

Filling the gap in competency-based training for medical oncology with supervised online patient counseling: A qualitative study

ASCO: MD Anderson’s Sharon Giordano and Richard Gorlick honored as 2024 Special Awards Recipients

Pathways Study Genotype Data, Alliance A011502 Secondary Analysis Headline Roswell Park ASCO24 Presentations

Phase Ib Study of Regorafenib (REG) Plus Pembrolizumab (PEMBRO) for First-Line Treatment of Advanced Hepatocellular Carcinoma (HCC)

Breaking Barriers for Cancer Clinical Trials: A Multi-Tiered Interventional Approach to Boost Racial and Ethnic Minority Participation in Early-Phase Studies

New Survival Data From a Lung Cancer Study to be Revealed by Yale Cancer Center Expert at International Conference

Cedars-Sinai Experts Present Cancer News at ASCO Annual Meeting

ASCO: Large precision oncology study identifies differences in prostate cancer genomics among a racially and ethnically diverse cohort of U.S. veterans

Filters